Some Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders may be a little concerned to see that the President, Anish Bhatnagar, recently sold a substantial US$966k worth of stock at a price of US$45.78 per share. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 2.9%.
Soleno Therapeutics Insider Transactions Over The Last Year
Notably, that recent sale by President Anish Bhatnagar was not the only time they sold Soleno Therapeutics shares this year. They previously made an even bigger sale of -US$5.8m worth of shares at a price of US$46.14 per share. So we know that an insider sold shares at around the present share price of US$44.52. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
Soleno Therapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
I will like Soleno Therapeutics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Insider Ownership Of Soleno Therapeutics
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Soleno Therapeutics insiders own 0.3% of the company, worth about US$6.9m. We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Soleno Therapeutics Insiders?
Insiders sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. We'd certainly practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Soleno Therapeutics. Be aware that Soleno Therapeutics is showing 3 warning signs in our investment analysis, and 1 of those can't be ignored...
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
